Medtronic has mitigated the impact of COVID-19 on its revenues by taking market share from competitors in key markets, including neurostimulation, drug-eluting stents, cardiac rhythm management and robotic spine surgery.
“As we head into our fourth quarter, we’re bullish on the recovery and our ability to return to growth and outpace our competitors,” Medtronic CEO Geoff Martha said during the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?